Figures computed from official regulatory filings — .
Analysttarget 10 USD (+88%) · consensus 4/5 · 1 buy · 0 hold · 0 sell
Ownershipinsiders 0.95% · institutions 21.25% · short 0.2% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for CNS Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.
Market information source · Oct 5, 2026
SEC company identity · Oct 5, 2026
Open-market timeline · full history
15 buys17 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| Fisher Michal | Buy | $10K | conv 50First in 12mo |
| SEC |
| Levin Rami | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Levin Rami | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Charles Faith L. | Buy | $34K | conv 57First in 12mo | SEC |
| O'Loughlin Steve | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Faulkner Eric | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Levin Rami | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Mahery Amy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Cockroft Bettina M. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Climaco John Mtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Downs Christophertrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Charles Faith L. | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Gumulka Jerzy | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Keyes Jeffry R.track record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Climaco John Mtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Mahery Amy | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Evans Carl Anthony | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Keyes Jeffry R.track record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Charles Faith L. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Charles Faith L. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Cockroft Bettina M. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Gumulka Jerzy | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Cockroft Bettina M. | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Climaco John Mtrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |
| Downs Christophertrack record | AwardD (derivative) | n/a (No price was disclosed in the filing) | SEC |